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Results: The study included 65 women and 35 men, with 77%
being White, 18% African American, 2% Asian, and 3% Other.
Mean age of the subjects was 63.5 years (± 8.7). 54% of the
subjects reported daily vitamin D supplementation, with 31%
taking <400 IU vitamin D and 23% taking ≥400 IU. Mean base-
line serum (OH)D level was 31.6 (± 12.6) ng/ml, with 47% of
subjects found to be vitamin D deﬁcient. Many subjects were
vitamin D deﬁcient in spite of supplementation (42% who took
≤400 IU vitamin D, and 30% of those taking >400 IU vitamin
D). However, after adjustment for age, gender, race, BMI, edu-
cation, and month of blood draw, vitamin D supplementation was
associated with decreased risk of vitamin D deﬁciency (subjects
taking 1-400 IU vitamin D vs. no-taking, OR = 0.51, 95% CI,
0.16-1.63; subjects taking >400 IU vitamin D vs. no-taking, OR
= 0.26, 95% CI, 0.07-1.04), p trend = 0.047. In these models,
lower vitamin D levels were inversely associated with education
(college graduate or above vs. under, OR = 0.28, 95% CI, 0.09-
0.84), and positively associated with African-American race (OR
= 4.10, 95% CI, 0.94-18.0).
Conclusions: Many individuals with knee OA are vitamin D
deﬁcient in spite of daily vitamin D supplementation. Current
recommendation with respect to vitamin D supplementation may
require reconsideration for individuals with OA.
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Purpose: Hip osteoarthritis (OA) is a debilitating musculoskeletal
disorder, characterized by chronic pain, affecting health related
quality of life. Lumiracoxib is a selective COX-2 inhibitor that
provides an alternative to traditional NSAIDs for the treatment of
OA. The present study was designed to demonstrate the efﬁcacy
and safety of lumiracoxib (100 mg od) compared with placebo in
patients with primary hip OA. Celecoxib (200 mg od) was used
as the positive control.
Methods: The primary efﬁcacy variables included patient’s global
assessment of disease activity (0-100 mm VAS), WOMAC™ 3.1
LK pain sub-scale score and WOMAC™ difﬁculty performing
daily activities (DPDA) sub-scale score (at Week 13). Prespec-
iﬁed secondary efﬁcacy variables included response to treat-
ment according to Osteoarthritis Research Society International
(OARSI) criteria at Weeks 4, 8 and 13; and minimal clinically im-
portant improvement (MCII) for hip OA pain by visit. The efﬁcacy
in the subgroup of patients ≥65 years was also prespeciﬁed to
be analyzed for these primary outcomes.
Results: A total of 1262 primary hip OA patients aged ≥40
years (490 were ≥65 years of age) were randomized to receive
lumiracoxib 100 mg od (n=427), celecoxib 200 mg od (n=419),
or placebo (n=416) over a period of 13 weeks. Lumiracoxib was
signiﬁcantly superior to placebo in all primary efﬁcacy variables
and provided similar pain relief compared with celecoxib at 13
weeks (in both overall population and ≥65 years sub group, Table
1). The treatment response in <65 age group was also similar
to the overall population and statistically signiﬁcant compared to
placebo.
Table 1. Efﬁcacy of lumiracoxib versus placebo for primary outcomes (estimated
difference after 13 weeks)
Lumiracoxib vs Placebo
LSM difference (95% CI)
Overall Population ≥65 years
Patient’s global assessment of
disease activity (VAS, mm) -8.59 (-11.84, -5.33)* -9.60 (-14.94, -4.25)*
WOMAC™ pain (0-20) scores -1.12 (-1.63, -0.60)* -1.63 (-2.48, -0.78)*
WOMAC™ DPDA (0-68) scores -3.58 (-5.24, -1.91)* -4.16 (-6.90, -1.42)**
*p<0.001, **p=0.003.
Similar results for all primary endpoints were observed for cele-
coxib vs placebo in the overall population and patients ≥65 years.
A greater proportion of patients in the lumiracoxib group (63.0%,
67.0%, 65.8%) had a treatment response according to OARSI
criteria at Weeks 4, 8 and 13 compared with placebo (45.4%,
50.0%, 53.6%) and the response was similar to that in the cele-
coxib group (63.7%, 67.5%, 67.8%). Lumiracoxib and celecoxib
were statistically superior to placebo in the achievement of MCII
for target hip OA pain after 4 weeks (p≤0.001; p=0.004), 8 weeks
(both p≤0.001), and 13 weeks (both p≤0.001) of treatment. The
incidence of adverse events in the lumiracoxib, celecoxib and
placebo groups was 56.4%, 53% and 47.6%, respectively. The
overall percentage of serious adverse events (SAEs) was 1.9%,
1.0% and 2.2% in the respective groups. There were no fatal
SAEs in the lumiracoxib and placebo groups. Two deaths oc-
curred in the celecoxib group that were not suspected to be
study drug related. Two patients (0.5%) had AST and/or ALT
elevations >3 x ULN in the placebo group versus no elevations
in the active treatment groups.
Conclusions: Lumiracoxib 100 mg od and celecoxib 200 mg od
were well tolerated and provided similar pain relief and improve-
ment in functional status in patients with primary hip OA. Efﬁcacy
was maintained in patients ≥65 years.
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Purpose: The placebo effect is inherent to all treatments. Phar-
macotherapy trials assess whether speciﬁc effects of an agent
are signiﬁcantly greater than non-speciﬁc inﬂuences (placebo) on
treatment outcomes. In OA trials, rates of placebo response often
approach or exceed 50%. Despite this, very little is known about
sociodemographic or clinical predictors of placebo response.
Methods: Data were drawn from placebo arm of North Amer-
ican patients in a large clinical trial designed to evaluate the
clinical effects of risedronate on knee OA (KOSTAR). OARSI
pain criteria (20% and 50% decrease in WOMAC pain) were
used to classify participants at 6 months as placebo respon-
ders. We examined whether placebo response was associated
with baseline demographic, clinical, and radiographic parameters
including: age, gender, race, BMI, work status, WOMAC (pain,
stiffness, function), patient global assessment, OA at other sites,
NSAID, analgesic and glucosamine use, joint space width (JSW)
and osteophyte grade.
Results: Of 311 OA patients who started the trial, 269 (86%)
completed the 6 month evaluations. Subjects were mostly female
(60%) and white (84%) with a mean (± SD) age of 60.4 ±
8.9, BMI of 30.2 ± 5.0, OARSI osteophyte grade of 1.6 ±
0.6 and baseline pain (WOMAC) of 35.1 ± 21.5. Nearly half
(49%) reported a 20% decrease in pain while 29% reported a
50% decrease, with no between-group differences by gender or
